miércoles, 26 de enero de 2011

2011 NHPC: Connecting HIV Prevention Professionals through Social Media

ESTIMADOS COLEGAS , ESTA INFORMACION ES MUY IMPORTANTE.

SALUDOS

DR. CARLOS ERAZO

"The 2011 National HIV Prevention Conference (NHPC) Exit Disclaimer Talk HIV Exit Disclaimer will be held in Atlanta, August 14-17. The conference will contribute to achieving the three major goals of the National HIV/AIDS Strategy, and these goals are reflected in the conference theme “The Urgency of Now: Reduce incidence. Improve access. Promote equity.” We want you to share your significant work in HIV prevention. We encourage you to submit an abstract Exit Disclaimer to the conference (deadline, February 4, 2011).
As we plan for the conference, we are looking at the next generation of HIV prevention leaders for inspiration on new methods of reaching at-risk populations and youth where they receive messages. Exploring the possibilities of social media allows prevention partners to learn from these innovative young public health professionals and help learn how to bridge a gap in prevention education and communication. This is particularly important as we look for the best ways to achieve the goals of the National Strategy.
Social media prevention campaigns are fast becoming a powerful channel to reach young consumers of health information, namely in the way of peer-to-peer online education. For example, through the Talk HIV Exit Disclaimer phase of the Act Against AIDS Exit Disclaimer campaign, CDC is leveraging social media to encourage open and honest conversations about HIV/AIDS and drive discussion both online and offline.
During this past year, we have seen how social media has also played an integral role in helping new and experienced HIV prevention professionals engage in pivotal discussions on HIV prevention, share the latest resources, and network with colleagues at conferences. During the 2011 NHPC, we hope to engage attendees to join in the discussions throughout the conference and share their experiences with their colleagues and the next generation of HIV prevention leaders. We encourage all professionals to take their years of experience in working with HIV, whether just a few years or 30, and share it with their colleagues and a new set of public health professionals working to find new ways to educate people about the disease.
Highlighting Young Innovators  This year’s NHPC will highlight the work of these young innovators in HIV research, prevention, and/or policy to encourage their continued contribution to the field of HIV prevention. To be considered for this recognition, new researchers should be under 30 years old and are required to submit a completed Sponsored Participant Application by the abstract submission deadline of February 4, 2011.
Follow us on Twitter.  You can follow the conference on Twitter at www.twitter.com/2011NHPC Exit Disclaimer for important conference reminders and news. Search Twitter using hashtag #2011NHPC to follow the conversations about the conference and include the hashtag in all of your conference-related tweets.
AIDS.gov note: Speaking of conferences, the International AIDS Society recently released its report on the 2011 International AIDS Conference in Vienna. Check out page 22 to read about how they used (and evaluated) social media at the conference."

http://blog.aids.gov/2011/01/2011-nhpc-connecting-hiv-prevention-professionals-through-social-media.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+aids%2Fgov+%28Blog.AIDS.gov%29

Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTIcontaining NRTI plus non-NRTI or only NRTI

Estimados colegas aquí les dejo un nuevo artículo sobre el tratamiento de VIH/Sida.

Saludos

Dr. Carlos Erazo

"Abstract
Background: Data regarding CD4+ recovery after switching from protease inhibitor (PI)-based
regimens to regimens not containing PI are scarce.
Methods: Subjects with virological success on first-PI-regimens who switched to NNRTI therapy
(NNRTI group) or to nucleoside reverse transcriptase (NRTI)-only (NRTI group) were studied. The
effect of the switch on the ongoing CD4+ trend was assessed by two-phase linear regression (TPLR),
allowing us to evaluate whether a change in the CD4+ trend (hinge) occurred and the time of its
occurrence. Furthermore, we described the evolution of the frequencies in CD4-count classes across
four relevant time-points (baseline, before and immediately after the switch, and last visit). Finally, we explored whether the CD4+ counts evolved differently in patients who switched to NNRTI or NRTI only regimens by considering: the overall CD4+ trends, the time to CD4+≥500/mm3 after the switch, and the area-under-the-curve (AUC) of the CD4+ after the switch.
Results: Eight hundred and ninety-six patients, followed for a median of 2,121 days, were included.
At TPLR, hinges occurred in 581/844 (68.9%), but in only 40/581 (6.9%) within a time interval (180
days) compatible with a possible relationship to the switch; furthermore, in 19/40 cases, CD4+ counts
appeared to decrease after the hinges. In comparison with the NNRTI group, the NRTI group showed
CD4+ count greater at baseline (P=0.0234) and before the switch (P≤0.0001), superior CD4+ T-cell
increases after HAART was started, lower probability of not achieving CD4+ ≥500/mm3 (P=0.0024),
and, finally, no significant differences in the CD4+ T-cell AUC after the switch after adjusting for
possible confounders (propensity score and pre-switch AUC). Persistence at CD4+ <200/mm3 was
observed in 34/435 (7.5%) patients, and a decrease below this level was found in only 10/259 (3.9%)
with baseline CD4+ ≥350/mm3.
Conclusions: Switching from first-line PI to NNRTI- or NRTI-based regimens did not seem to impair
CD4+ trend over long-term follow-up. Although the greater CD4+ increases in patients who switched
to the NRTI-only regimen was due to higher CD4+ counts before the switch, several statistical
analyses consistently showed that switching to this regimen did not damage the ongoing immunereconstitution.
Lastly, the observation that CD4+ T-cell counts remained low or decreased in the long term despite virological success merits further investigation

http://www.biomedcentral.com/content/pdf/1471-2334-11-23.pdf

INFORME DEL INH SOBRE LOS CASOS CONFIRMADOS POR WB 2010

ESTIMADOS COLEGAS TENEMOS EL SIGUIENTE REPORTE DEL INH




EN LAS 26 CLINICAS SE HAB CONSEGUIDO 7090 PRE CONSEJERIAS DURANTE EL
TERCER CUTRIMESTRE (SEPTIEMBRE-OCTUBRE-NOVIEMBRE Y DICIEMBRE)

SE HAN PRESENTADO 3271 DEMANDAS ESPONTANEAS


SE HAN REALIZADO 11838 PRUEBAS DE TAMIZAJE


DOBLEMENTE REACTIVAS  1779


CONFIRMADAS 1392


SE HAN REALIZADO 4950 DETERMINACIONES DE CD4 CD8 EN LOS PVVS A NIVEL
NACIONAL.

SE HAN REALIZADO 4140 DETERMINACIONES DE CARGA VIRAL PARA VIH

MONITOREABNDO EL TRATAMIENTO TARV.


EXISTE UNA CONCORDANCIA DEL 98.5% EN LOS 26 LABORATORIOS EN CUANTO A
LA PROEFICIENCIA PARA PRUEBAS RAPIDAS  COMPARADOS CON EL PANEL
NACIONAL DE REFERENCIA.



SALUDOS

DR. CARLOS ERAZO